Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Equities
TEVA
IL0006290147
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,204 ILa | -0.50% | +1.22% | +62.62% |
Sales 2024 * | 15.95B 5,853B | Sales 2025 * | 16.52B 6,064B | Capitalization | 19.12B 7,018B |
---|---|---|---|---|---|
Net income 2024 * | 820M 301B | Net income 2025 * | 1.39B 509B | EV / Sales 2024 * | 2.13 x |
Net Debt 2024 * | 14.93B 5,478B | Net Debt 2025 * | 12.41B 4,555B | EV / Sales 2025 * | 1.91 x |
P/E ratio 2024 * |
18
x | P/E ratio 2025 * |
12.5
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.44% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | -0.50% | ||
1 week | +1.22% | ||
Current month | +17.68% | ||
1 month | +27.00% | ||
3 months | +24.73% | ||
6 months | +73.30% | ||
Current year | +62.62% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 59 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 6,204 | -0.50% | 377 358 |
24-05-22 | 6,235 | +2.55% | 1,656,060 |
24-05-21 | 6,080 | -1.47% | 1,066,624 |
24-05-20 | 6,171 | +1.83% | 1,405,843 |
24-05-19 | 6,060 | -1.13% | 675,025 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 23, 2024 at 08:04 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 723B | |
+34.39% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.04% | 244B | |
+9.80% | 208B | |
-4.17% | 205B | |
+2.81% | 168B |
- Stock Market
- Equities
- TEVA Stock
- TEVA Stock